SUBSCRIBE
SUBSCRIBE
News   Drug Development

Inspire Pharmaceuticals, Inc. Initiates Phase 2 14-Day Clinical Trial Of Epinastine For Seasonal Allergic Rhinitis

December 5, 2006 | 
1 min read
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis.
Clinical research Phase 2
MORE ON THIS TOPIC
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Amgen’s rare disease drug Tavneos tied to 20 deaths in Japan
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Sorting garbage concept. Cropped photo of paper thash. Crumple paper falling to the recycling bin
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
May 15, 2026
 · 
2 min read
 · 
Gabrielle Masson
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
 · 
3 min read
 · 
Annalee Armstrong